Serum Level of Ligand Programmed Death-1 in Endometriosis

In: Open Access Macedonian Journal of Medical Sciences · 2022 · vol. 10(B) , pp. 797–802 · doi:10.3889/oamjms.2022.8733 · W4224289927
article OA: diamond CC0
AI-generated summary by claude@2026-06, 2026-06-07

Serum levels of PDL1, CA125, IL-6, IL-8, TNF, and VEGF were significantly different between endometriosis patients and controls, with correlations found between PDL1 and CA125, IL-8, and TNF.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-07, 2026-07-16 · read from full text

This study evaluated serum programmed death-1 ligand (PD-L1) levels in patients with genital endometriosis, measuring PD-L1 along with CA-125, IL-6, IL-8, TNF, and VEGF in venous blood collected 1 hour before surgery and/or treatment. Twenty-one endometriosis patients were analyzed using stratification based on the presence or absence of endometriosis according to the revised American Society for Reproductive Medicine classification. Compared with controls, the endometriosis group had a higher PDL-1 level (55.32 ng/ml vs 19.72 ng/ml; p < 0.001), higher CA-125, elevated pro-inflammatory cytokines (IL-6, IL-8, TNF), and approximately doubled VEGF, and correlations were reported between PDL-1 and CA-125/IL-8/TNF and a moderate association with VEGF. The authors note that larger studies are required, implying limited generalizability due to the small sample size. This paper is centrally about endometriosis — it measures and correlates serum PD-L1 (PD-1/PD-L1 axis) alongside inflammatory markers and CA-125 in genital endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

AIM: In this study, is to evaluate serum level of ligand programmed death-1 (PDL1) in patients with genital endometriosis. MATERIAL AND METHODS: For PDL-1, cancer antigen 125 (CA 125), interleukin (IL)-6, IL-8, tumor necrosis factor (TNF), and vascular endothelial growth factor (VEGF) determination, venous blood was taken 1 h before surgery and/or treatment. All patients were stratified by the presence or absence of endometriosis according to the American Society of Reproductive Medicine’s Revised Classification of Endometriosis of the American Society of Reproductive Medicine. RESULTS: Twenty-one patients with endometriosis participated in the study. The PDL-1 level an experienced group was 55.32 ng/ml (interquartile range [IQR] 34.53–76.20); in the control group was 19.72 ng/ml (IQR 14.72–24.78), which was a statistically significant decrease (p < 0.001). A significant increase in CA125 31.87 (IQR 15.43–36.96) was detected (p < 0.001). In the experimental group, all pro-inflammatory cytokines were elevated (IL-6, IL-8, and TNF, p < 0.013; <0.001; and <0.001) and almost twice increased VEGF 243.44 (IQR 194.56–328.07), (p = 0.016). A noticeable correlation was found between the following indicators PDL-1-CA125, PDL-1-IL-8, and PDL-1-TNF, and a moderate correlation was found between PDL-1 and VEFF (p = 0.006). CONCLUSIONS: The results of the study showed that the levels of PDL-1, CA 125, IL-6, IL-8, TNF, and VEGF were statistically significantly different in the experimental and control groups, and a correlation was also revealed between the levels of PDL-1 and CA125, IL-8 and TNF in patients with genital endometriosis. Therefore, further studies with larger numbers of patients are required.
Full text 7,757 characters · extracted from oa-doi-fallback · 4 sections · click to expand

Material and methods

For PDL-1, cancer antigen 125 (CA 125), interleukin (IL)-6, IL-8, tumor necrosis factor (TNF), and vascular endothelial growth factor (VEGF) determination, venous blood was taken 1 h before surgery and/or treatment. All patients were stratified by the presence or absence of endometriosis according to the American Society of Reproductive Medicine’s Revised Classification of Endometriosis of the American Society of Reproductive Medicine.

Results

Twenty-one patients with endometriosis participated in the study. The PDL-1 level an experienced group was 55.32 ng/ml (interquartile range [IQR] 34.53–76.20); in the control group was 19.72 ng/ml (IQR 14.72–24.78), which was a statistically significant decrease (p < 0.001). A significant increase in CA125 31.87 (IQR 15.43–36.96) was detected (p < 0.001). In the experimental group, all pro-inflammatory cytokines were elevated (IL-6, IL-8, and TNF, p < 0.013; <0.001; and <0.001) and almost twice increased VEGF 243.44 (IQR 194.56–328.07), (p = 0.016). A noticeable correlation was found between the following indicators PDL-1-CA125, PDL-1-IL-8, and PDL-1-TNF, and a moderate correlation was found between PDL-1 and VEFF (p = 0.006).

Conclusions

The results of the study showed that the levels of PDL-1, CA 125, IL-6, IL-8, TNF, and VEGF were statistically significantly different in the experimental and control groups, and a correlation was also revealed between the levels of PDL-1 and CA125, IL-8 and TNF in patients with genital endometriosis. Therefore, further studies with larger numbers of patients are required.Downloads Metrics Plum Analytics Artifact Widget Block

References

Prescott J, Farland LV, Tobias DK, Gaskins AJ, Spiegelman D, Chavarro JE, et al. A prospective cohort study of endometriosis and subsequent risk of infertility. Hum Reprod. 2016;31(7):1475-82. https://doi.org/10.1093/humrep/dew085 PMid:27141041 DOI: https://doi.org/10.1093/humrep/dew085 Tanbo T, Fedorcsak P. Endometriosis-associated infertility: Aspects of pathophysiological mechanisms and treatment options. Acta Obstet Gynecol Scand. 2017;96(6):659-67. https://doi.org/10.1111/aogs.13082 PMid:27998009 DOI: https://doi.org/10.1111/aogs.13082 Hadisaputra W, Prayudhana S. Serum biomarker profiles of interleukin-6, tumor necrosis factor-alpha, matrix-metalloproteinase-2, and vascular endothelial growth factor in endometriosis staging. Med J Indones. 2013;22:76-82. DOI: https://doi.org/10.13181/mji.v22i2.532 Walankiewicz M, Grywalska E, Polak G, Korona-Glowniak I, Witt E, Surdacka A, et al. The increase of circulating PD-1- and PD-L1-expressing lymphocytes in endometriosis: Correlation with clinical and laboratory parameters. Mediat Inflamm. 2018;2018:7041342. https://doi.org/10.1155/2018/7041342 PMid:30595667 DOI: https://doi.org/10.1155/2018/7041342 Gao Y, Shi S, Ma W, Chen J, Cai Y, Ge L, et al. Bibliometric analysis of global research on PD-1 and PD-L1 in the field of cancer. Int Immunopharmacol. 2019;72:374-84. https://doi.org/10.1016/j.intimp.2019.03.045 PMid:31030093 DOI: https://doi.org/10.1016/j.intimp.2019.03.045 Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009;229(1):114-25. https://doi.org/10.1111/j.1600-065X.2009.00767.x PMid:19426218 DOI: https://doi.org/10.1111/j.1600-065X.2009.00767.x McKay JT, Egan RP, Yammani RD, Chen L, Shin T, Yagita H, et al. PD-1 suppresses protective immunity to Streptococcus pneumoniae through a B cell-intrinsic mechanism. J Immunol. 2015;194(5):2289-99. https://doi.org/10.4049/jimmunol.1401673 PMid:25624454 DOI: https://doi.org/10.4049/jimmunol.1401673 Lim TS, Chew V, Sieow JL, Goh S, Yeong JP, Soon AL, et al. PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity. Oncoimmunology. 2016;5(3):e1085146. https://doi.org/10.1080/2162402X.2015.1085146 PMid:27141339 DOI: https://doi.org/10.1080/2162402X.2015.1085146 Barros IB, Malvezzi H, Gueuvoghlanian-Silva BY, Piccinato CA, Rizzo LV, Podgaec S. What do we know about regulatory T cells and endometriosis? A systematic review. J Reprod Immunol. 2017;120:48-55. https://doi.org/10.1016/j.jri.2017.04.003 PMid:28463710 DOI: https://doi.org/10.1016/j.jri.2017.04.003 Wu L, Lv C, Su Y, Li C, Zhang H, Zhao X, et al. Expression of programmed death-1 (PD-1) and its ligand PD-L1 is upregulated in endometriosis and promoted by 17beta-estradiol. Gynecol Endocrinol. 2019;35(3):251-6. https://doi.org/10.1080/09513590.2018.1519787 PMid:30325236 DOI: https://doi.org/10.1080/09513590.2018.1519787 Mol BW, Bayram N, Lijmer JG, Wiegerinck MA, Bongers MY, van der Veen F, et al. The performance of CA-125 measurement in the detection of endometriosis: A meta-analysis. Fertil Steril. 1998;70(6):1101-8. https://doi.org/10.1016/s0015-0282(98)00355-0 PMid:9848302 DOI: https://doi.org/10.1016/S0015-0282(98)00355-0 Hirsch M, Duffy JM, Deguara CS, Davis CJ, Khan KS. Diagnostic accuracy of cancer antigen 125 (CA125) for endometriosis in symptomatic women: A multi-center study. Eur J Obstet Gynecol Reprod Biol. 2017;210:102-107. https://doi.org/10.1016/j.ejogrb.2016.12.002 PMid:27987404 DOI: https://doi.org/10.1016/j.ejogrb.2016.12.002 Karimi-Zarchi M, Dehshiri-Zadeh N, Sekhavat L, Nosouhi F. Correlation of CA-125 serum level and clinico-pathological characteristic of patients with endometriosis. Int J Reprod Biomed. 2016;14(11):713-8. PMid:28008424 DOI: https://doi.org/10.29252/ijrm.14.11.713 Mihalyi A, Gevaert O, Kyama CM, Simsa P, Pochet N, De Smet F, et al. Non-invasive diagnosis of endometriosis based on a combined analysis of six plasma biomarkers. Hum Reprod. 2010;25(3):654-64. https://doi.org/10.1093/humrep/dep425 PMid:20007161 DOI: https://doi.org/10.1093/humrep/dep425 Machairiotis N, Vasilakaki S, Thomakos N. Inflammatory mediators and pain in endometriosis: A systematic review. Biomedicines. 2021;9(1):54. https://doi.org/10.3390/biomedicines9010054 PMid:33435569 DOI: https://doi.org/10.3390/biomedicines9010054 Mckinnon B, Mueller MD, Nirgianakis K, Bersinger NA. Comparison of ovarian cancer markers in endometriosis favours HE4 over CA125. Mol Med Rep. 2015;12(4):5179-84. https://doi.org/10.3892/mmr.2015.4062 PMid:26165164 DOI: https://doi.org/10.3892/mmr.2015.4062 Xavier P, Belo L, Beires J, Rebelo I, Martinez-de-Oliveira J, Lunet N, et al. Serum levels of VEGF and TNF-alpha and their association with C-reactive protein in patients with endometriosis. Arch Gynecol Obstet. 2006;273(4):227-31. https://doi.org/10.1007/s00404-005-0080-4 PMid:16208475 DOI: https://doi.org/10.1007/s00404-005-0080-4 Sbracia M, Valeri C, Antonini G, Biagiotti G, Pacchiarotti A, Pacchiarotti A. Fas and fas-ligand in eutopic and ectopic endometrium of women with endometriosis: The possible immune privilege of ectopic endometrium. Reprod Sci. 2016;23(1):81-6. https://doi.org/10.1177/1933719115594019 PMid:26156853 DOI: https://doi.org/10.1177/1933719115594019 Downloads Published How to Cite Issue Section Categories License Copyright (c) 2022 Lyudmila Akhmaltdinova, Leila Appazova, Yasminur Turdybekova, Irina Kopobayeva, Zhanna Amirbekova, Igor Marinkin (Author) This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (18)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK